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Peptide Antagonism and T Cell Receptor
Interactions with Peptide-MHC Complexes
Clone 2C arose in an H-2b mouse (BALB/b strain) im-
munized with H-2d cells (from DBA/2 and BALB/c mice).
It responds to the class I MHC protein Ld (an alloreaction)
Yuri Sykulev,*§ Yulia Vugmeyster,* Anders Brunmark,²
Hidde L. Ploegh,* and Herman N. Eisen*³
*Center for Cancer Research and Department of Biology
Massachusetts Institute of Technology in association with naturally processed peptides (e.g.,
LSPFPFDL, termed p2Ca; Udaka et al., 1992) that deriveCambridge, Massachusetts 02139
²Department of Immunology from a ubiquitous intracellular protein (a-ketoglutarate
dehydrogenase; Udaka et al., 1993). Using the alloreac-The Scripps Research Institute
La Jolla, California 92037 tive cytolytic responses to Ld1 target cells loaded with
diverse variants of p2Ca, we were unable to identify
antagonist peptides. Subsequently, Udaka et al. (1996)
discovered that 2C CTL can respond vigorously to aSummary
synthetic peptide, SIYRYYGL (here termed SYRGL), in
association with Kb, which is syngeneic for 2C cells.We describe antagonist peptides that specifically in-
Using highly sensitive cytolytic assays based on SYRGL-hibit cytolytic activity of T cell clones and lines that
pulsed Kb1 target cells, we describe here several natu-express the antigen-specific receptor of CD81 T lym-
rally occurring peptides that act as antagonists for thephocyte clone 2C, which recognizes peptides in asso-
2C TCR.ciation with syngeneic (Kb) and allogeneic (Ld) MHC
One of the antagonists (RGYVYQEL, termed EVSV) isproteins. Addition of an antagonist peptide that can
of interest because of two findings. First, in contrast tobind to Kb on 2C cells decreased the tyrosine phos-
the few previous comparisons between antagonist andphorylation of CD3 z chains elicited by prior exposure
agonist pMHC complexes, we found that the EVSV-Kbof the cells to an agonist peptide-Kb complex. Contrary
complex is bound with about 30 times higher affinity byto previous agonist-antagonist comparisons, the 2C
the 2C TCR than the weak agonist p2Ca-Kb complex.T cell receptor had higher affinity for an antagonist
Second, the addition of the EVSV antagonist peptide topeptide-Kb complex than for a weak agonist peptide-
2C cells after they had been briefly in contact with anKb complex. This difference is considered in light of
immobilized agonist-MHC complex (SYRGL-Kb) broughtevidence that antigen-specific receptor affinity values
about a rapid and profound decrease in tyrosine phos-can be substantially higher when determined with the
phorylation of the cells' CD3 z chains. In consideringreceptor on live cells than with the receptor in cell-
the significance of the affinity difference between thefree systems.
antagonist and agonist complexes, we note that there
can be substantial differences between TCR affinity val-
ues determined with the receptor on intact cells and inIntroduction
cell-free systems. The sequences of all the peptides
discussed below and the terms used to designate themThe nature of a T cell's response to complexes formed
are listed in Table 1 and Figure 2 (see below).by peptides with major histocompatibility (MHC) pro-
teins (pMHC complexes) can be greatly affected by vari-
ations in the peptide's amino acid sequence (Kersh and Results
Allen, 1996). Some peptides (agonists) elicit the full
range of known responses; others (partial agonists), of- The Cytolytic Assay for Antagonist Peptides
As shown in Figure 1A, half-maximal lysis of an optimalten differing from agonists by only one or a few amino
acid residues, elicit partial responses (i.e., effector but Kb1 target cell (T2-Kb) was achieved with the SYRGL
peptide at the extraordinarily low concentration ofnot proliferative responses); and the principal effect of
still others (antagonist peptides) is to inhibit the activity around 5 3 10214 M (SD50 value). Since SYRGL and a
peptide RGYVYQG (VSV) from vesicular stomatatis virusof agonists. Although a role for antagonist peptides in
normal immune responses is not entirely clear, these (VSV) were about equally effective in blocking the Kb-
dependent cytolytic activity of an unrelated CTL clonepeptides are of considerable interest because they pro-
vide the tools for exploring previously unappreciated (4G3, specific for Kb plus the ovalbumin peptide SIIN-
FEKL [pOV8]) (Figure 1C; Table 1), it appears that thecomplexities in the responses of T cells to ligation of
their antigen-specific receptor (T cell receptor or TCR). affinity of Kb for SYRGL is close to its previously mea-
sured affinity for VSV (1 3 108 M21; Matsumura et al.,We have accordingly sought to identify antagonist pep-
tides for the CD8 cytotoxic T cell known as 2C, a clone 1992). In accord with the low SD50 value (Sykulev et
al., 1996), we found that soluble SYRGL-Kb complexeswhose TCR recognizes defined allogenic and syngeneic
pMHC complexes. bound to the TCR on live 2C cells with the relatively
high affinity of 1 3 107 M21 (Figure 1D; Tables 1 and 2).
To identify antagonist peptides for the 2C TCR, we
³ To whom correspondence should be addressed (e-mail: hneisen@ took advantage of the SYRGL peptide's potency as an
mit.edu).
agonist to pulse T2-Kb target cells (51Cr labeled) with this§ Present address: Department of Microbiology and Immunology,
peptide at 5 3 10214 M, leaving a large number of emptyKimmel Cancer Institute, Thomas Jefferson University, Philadelphia,
Pennsylvania 19107. Kb molecules that could be loaded with other peptides.
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Figure 1. Recognition of Synthetic Peptide
SIYRYYGL by 2C CTL
(A) Specific lysis of 51Cr-labeled T2-Kb tar-
get cells by 2C CTL in the presence of
SYRGL and other Kb-binding peptides at vari-
ous concentrations. Peptides were SIYRYYGL
(SYRGL, filled circles), SIINFEKL (pOV8, open
triangles), LSPFPFDL (p2Ca, open circles),
LSPYPFDL (p2Ca-Y4, open squares), and
RGYVYQGL (VSV, filled squares).
(B) Specific lysis of 51Cr-labeled Con A±acti-
vated splenocytes (Con A blasts) from TAP-
deficient mice (H-2b) by 2C CTL in the pres-
ence of various concentrations of the strong
agonist peptide SYRGL (filled circles) and two
weak agonist peptides, naturally processed
p2Ca (open circles) and dEV8 (filled triangles).
Note the difference in peptide concentration
required for half-maximal lysis of these sub-
optimal target cells and the optimal target
cells in (A).
(C) Relative affinity of Kb for two peptides,
SYRGL and VSV, estimated from effective-
ness of blocking a Kb-dependent cytolytic re-
action. Shown is the specific lysis of T2-Kb
target cells sensitized with pOV8 by pOV8-Kb-specific CTL (clone 4G3) in the absence (dotted) or presence (solid curves) of various concentra-
tions of SYRGL (filled circles) or VSV (filled squares). SYRGL and VSV alone did not elicit a cytolytic reaction with these CTL. For peptide
sequences, see legend for (A).
(D) Affinity of the TCR on live 2C cells for the SYRGL-Kb complex.
Amount of radiolabeled Fab9 fragments of the clonotypic anti-2C TCR antibody (1B2) specifically bound to the TCR on live 2C cells (clone
L3.100) in the absence (Bo) or presence (B) of various concentrations of the SYRGL-Kb complex.
(E) Ligation of TCR molecules on 2C CTL by a clonotypic TCR-specific antibody (1B2; Kranz et al., 1984) decreases specific lysis of SYRGL-
pulsed T2-Kb target cells. The extent of target cell lysis in the absence of the 1B2 antibody is indicated by a dotted line. About 80% of 2C
TCR had to be blocked by the antibodies to decrease specific lysis of the target cells by half. Percent occupancy (a) of the TCR was calculated
as a 5 (K´C/(1 1 K´C)) 3 100, where C is free concentration of 1B2 Fab9 fragment (assumed to be the same as the total concentration) and
K is the equilibrium binding constant (2 3 108 M21) for the reaction between 2C TCR and 1B2 Fab9. The concentration of free SYRGL was
4 3 10214 M.
These pulsed target cells were then incubated with di- less stable complexes with antagonist than with agonist
ligands (Alam et al., 1996; Lyons et al., 1996). We pre-verse test peptides and various CD81 CTL that ex-
pressed the 2C TCR, including the original 2C clone and viously found the 2C TCR affinity for the weak agonist
p2Ca-Kb complex to be about 3 3 1023 M21, at the lowerseveral 2C TCR1 T cell clones from 2C TCR transgenic
mice. When added alone to T2-Kb cells, the tested pep- limit of what can be measured on live cells (Sykulev et
al., 1994a). Accordingly, we expected the 2C TCR affinitytides behaved either as weak agonists (high SD50 values)
or elicited no cytolytic activity (Figure 1A). for the antagonist EVSV-Kb complex to be still lower, i.e.,
to be essentially immeasurable on 2C cells. Surprisingly,
however, the affinity proved to be about 9 3 104 M21,Antagonist Peptides
As evident from Figure 2, lysis of the pulsed target cells or about 30-fold higher (Figure 4; Table 1).
was enhanced by two peptides (agonists), unaffected
by two others (null peptides), and inhibited by six others
Comparison of Different Target Cells(antagonists). The antagonist effects were not always
We attribute the detection of antagonist activity by aobserved: it appeared that they were more consistently
high proportion of the peptides tested to the sensitivityseen with recently derived clones than with those that
of the assay. It is likely that the use of T2-Kb as targethad been in culture for many months, and they were
cells was responsible for this sensitivity, as we did notnot observed with the original 2C clone. Representative
observe antagonism when the peptides were tested inresults are shown in Figures 3A, 3C, and 3D for three
the same way with two other Kb1 target cells, EL4 andnewly derived clones (L3.100, K2.30, and G3.1). We also
RMA-S. The advantage of T2-Kb cells was not that theyfound that polyclonal 2C TCR1 cell lines (derived as
were of human origin (the others are mouse cells) butdescribed below) were indistinguishable from clones L,
rather stems from two considerations: (1) for inhibitionK, and G in responding strongly to the SYRGL agonist
to be observed, antagonist peptide concentrations hadand in their susceptibility to inhibition by the antagonist
to greatly exceed the agonist peptide concentrationpeptides (Figure 3B).
used to pulse target cells (see Figure 3), and (2) much
higher agonist peptide concentrations were required toAffinity of the 2C TCR for an Antagonist
pulse EL4 and RMA-S than T2-Kb target cells. As a result,Peptide-MHC Complex
the antagonist concentrations needed to observe inhibi-The few comparisons that have been made between
tion could be readily achieved with T2-Kb but not withTCR binding of agonist and antagonist pMHC com-
plexes suggest that TCR have lower affinity and form the other target cells. The concentrations of agonist
TCR Recognition of Antagonist Peptide-MHC Complexes
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Table 1. 2C TCR Recognition of Diverse Peptides Associated with Syngeneic and Allogeneic MHC Class I Proteins and Various
Responses of 2C Cells to These Peptidesa
Peptideb Affinity (M21)c
Name Sequence MHC Activity MHC for Peptide TCR for pepMHC
SYRGL SIYRYYGL Kb agonist 1 3 108 1 3 107
EVSV RGYVYQEL antagonist 1 3 108 9 3 104
p2Ca LSPFPFDL agonist 4 3 104d 3 3 103d
VSV RGYVYQGL antagonist 1 3 108d ,103d
pOV8 SIINFEKL null 1 3 108d ,103d
p2Cb VAITRIEQLSPFPFDL Ld agonist 1 3 107 4 3 106
RL12 RIEQLSPFPFDL agonist 1 3 107 4 3 106
QL9 QLSPFPFDL agonist 2 3 108d 2 3 107d
p2Ca LSPFPFDL agonist 4 3 106d 2 3 106d
SL7 SPFPFDL agonist 6 3 106 1 3 106
PL4 PFDL agonist 6 3 103 1 3 105
p2Ca-Y4 LSPYPFDL agonist 2 3 107 4 3 106
QL9-Y5 QLSPYPFDL agonist 2 3 109 7 3 106
I1-QL9-Y5 QLSPY(I1)PFDL agonist 2 3 107 6 3 106
. . . VAITRIEQLSPFPFDLLLKE . . . a-ketoglutarate dehydrogenase (a-KGDH)
a 2C CD81 T cells are positively selected by Kb syngeneic class I MHC but also recognize an allogeneic MHC class I protein Ld in association
with peptides from a-ketoglutarate dehydrogenase (a-KGDH [Udaka et al., 1993]).
b Naturally processed peptides p2Ca, p2Cb, and p2Ca-Y4 are underlined (Udaka et al., 1992, 1993; Wu et al., 1995) and their analogs are
aligned to match the sequence of a-KGDH. FDL motif for Ld-binding peptides (Al-Ramadi et al., 1995; Robinson and Lee, 1996) is depicted
in bold. Naturally processed Kb restricted peptides are also underlined.
c Intrinsic affinities of soluble Ld and Kb proteins for the peptides shown were determined as previously described (Matsumura et al., 1992);
equilibrium binding constants of the TCR-pMHC reactions were measured from competition binding of the soluble pMHC complexes and
radiolabeled clonotypic anti-TCR (1B2) antibodies (Fab9 fragments) to TCR on live 2C cells (Sykulev and Eisen, 1997).
d Values reported previously (Matsumura et al., 1992; Sykulev et al., 1994a, 1994b).
Note: A previous reference to unpublished results showing that the DL dipeptide could sensitize target cells for lysis by 2C CTL (cited as an
addendum to Eisen et al., 1997) was mistaken, probably because the dipeptide preparations used were contaminated with traces of a strong
peptide agonist.
(SYRGL) chosen to pulse target cells were based on the degrees of efficacy; e.g., peptide concentrations for
half-maximal lysis ranged from about 1025 to 10212 Magonist concentration required for half-maximal lysis of
these cells (SD50 value); with EL4 and RMA-S target cells, (Sykulev et al., 1994a, 1994b; unpublished data).
In Table 1, the Ld-binding peptides are aligned from thethe SYRGL SD50 values were about 100 times higher
than for T2-Kb target cells (data not shown). All of these C-terminal leucine. This alignment was used because
systematic alanine substitutions of the p2Ca octapep-differences reflect the greater number of empty Kb mole-
cules available for peptide loading on T2-Kb than on tide and the QL9 nonapeptide had shown that the C-ter-
minal sequence FDL is critical for binding these peptidesEL4 and RMA-S cells. Although the total number of Kb
molecules on EL4 and T2-Kb cells are approximately the to Ld (Al-Ramadi et al., 1995; Robinson and Lee, 1996).
Stronger justification for viewing the peptides in registersame (about 5 3 105 per cell; unpublished data), the
peptide transporter TAP is defective in T2-Kb cells but from the C terminus has emerged with the recent de-
scription of the crystal structure of Ld (Balendiran et al.,not in EL4. While RMA-S is also transport defective,
there are far fewer Kb molecules on these cells than on 1997; Speir et al., 1998). Although 2C TCR affinity spans
a 200-fold range from the weakest (PL4-Ld) to the strong-T2-Kb, which expresses a transfected Kb gene. Figure
1B provides another example that shows the advan- est binding Ld-peptide complex (QL9-Ld), it is striking
how little the affinity values vary otherwise betweentage of T2-Kb over another Kb1 target cell (compare
Figure 1A). complexes that differ considerably in peptide length
(e.g., compare p2Cb, RL12, p2Ca, SL7, etc., in Table 1).
Allogeneic versus Syngeneic Reactions
Before Udaka et al. (1996) described the SYRGL peptide, How Do Antagonist Peptides Exert Their Effect?
In the cytolytic assay for antagonism, the target cellsour efforts to identify peptides that inhibit the reaction
of 2C cells with allogeneic (Ld1) target cells (T2-Ld), using were pulsed with the strong agonist peptide at about
10213 M before the test antagonist peptide was added.several Ld-binding peptides, were fruitless (Tsomides
et al., unpublished data). As shown in Table 1, these In view of this extremely low concentration, the number
of MHC-binding sites on target cells occupied by theallogeneic targets were used to examine a series of
peptides having sequences that are found in murine agonist is likely to be ,0.01% of total MHC sites. Hence
it is most unlikely that antagonists act by competinga-ketoglutarate dehydrogenase (shown at bottom of Ta-
ble 1; see Udaka et al., 1993). Although these Ld-binding with agonists for target cell MHC. Previous studies have
led to the same conclusion (Bertoletti et al., 1994; Eva-peptides varied from 4 to 16 amino acids in length,
they were all agonists for 2C cells, albeit with different vold et al., 1994; Klenerman et al., 1994).
Immunity
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Table 2. Differences in Equilibrium Constants for 2C TCR Interactions with Soluble Peptide-MHC Complexes Measured with the TCR
on Live 2C Cells or in a Cell-Free Systema,h
Equilibrium Binding Constant (Ka) of pepMHC
Complexes to 2C TCR, M21
Peptide-MHC TCR in a Cell-Free TCR on Live 2C
Complexesb Systemc Cellsd Re SD50, nMf
p2Ca-Ld 3 3 105g 2 3 106 7 0.5
QL9-Ld 3 3 105 2 3 107 68 0.005
p2Ca-Kb not measured 3 3 103 Ð 1,000
dEV8-Kb 1.2 3 104 not measured Ð $1,000
SYRGL-Kb 3 3 104 1 3 107 330 0.00004
a All values of equilibrium (affinity) constants shown in this table have been measured using recombinant MHC class I proteins Kb and Ld
expressed in a Drosophila melanogaster-based expression system (Jackson et al., 1992). Soluble 2C TCR was produced in the same system
(Garcia et al., 1996a, 1996b).
b For peptide sequences see Table 1 and Figure 2.
c Ka values calculated from association and dissociation rate constants measured from the binding of soluble pMHC to soluble immobilized
a,b-TCR by surface plasmon resonance (Garcia et al., 1996a).
d Ka values measured from direct binding of 125I-pMHC complexes or competition binding with the Fab9 fragments of the 1B2 clonotypic
antibody to the TCR on live 2C cells (see Table 1).
e R is a ratio of equilibrium binding constants for TCR-pMHC reaction measured with live cells and in a cell-free system.
f SD50 is a concentration of cognate peptide required to sensitize target cells (T2-Kb or T2-Ld, respectively) for half-maximal lysis by 2C CTL;
the value of SD50 inversely correlates with the efficacy of cytolysis.
g The reaction of soluble p2Ca-Ld complex with soluble immobilized 2C TCR was also analyzed by surface plasmon resonance by Corr et al.
(1994). Since the authors used the recombinant proteins produced in a different expression system, their data are not given here.
h In contrast to the cell free±live cell differences shown in this table, essentially no difference was found in the affinity values measured with
the TCR on live hybridoma cells or in a cell-free system for the reaction between the TCR of the 2B4 CD41 T cell clone and its pMHC ligand,
a moth cytochrome peptide (MCC) in association with the I-Ek MHC class II molecule (Matsui et al., 1991, 1994). Whether the results with the
latter system and the consistent disparities shown in the table are due to differences between CD4 and CD8, MHC I and MHC II molecules,
T cells and hybridomas, or other features remains to be determined.
To determine if antagonist pMHC complexes are in- fragments) in order to inhibit by 50% the specific lysis
of SYRGL-pulsed T2-Kb cells by 2C CTL (in the standardhibitory because they compete with agonist complexes
for binding to the TCR, we first determined the fraction 4 hr cytolytic assay) (Schodin et al., 1996). As shown in
Figure 1E, 50% inhibition of lysis required occupancyof 2C cells' TCR molecules that would have to be
blocked by the clonotypic anti-TCR antibody 1B2 (Fab9
Figure 2. Effect of Diverse Kb-Binding Peptides on Specific Lysis
of SYRGL-Pulsed T2-Kb Target Cells by 2C TCR1 Clone L3.100
Shown is the percent inhibition (filled bars) or enhancement (striped
bars) of specific target cell lysis in the presence of 1 mM of the
Figure 3. Inhibitory Effect of Various Peptides on Specific Lysis ofindicated peptides. The naturally processed peptides tested were
SYRGL-Pulsed T2-Kb Target Cells by Various CTL Clones and aLSPFPFDL (p2Ca [Udaka et al., 1992]), LSPYPFDL (p2Ca-Y4 [Wu et
Polyclonal CD81 Cell Line that All Express Transgenic 2C TCRal., 1995]), SIINFEKL (pOV8 [Carbone et al., 1992]), ANYDFICV (ANY
[Malarkannan et al., 1996]), EQYKFYSV (dEV8 [Tallquist and Pease, 2C clones ([A], L3.100; [C], G3.1; and [D], K2.30) and the cell line
(B) were derived from the spleens of 2C TCR transgenic mice (H-2b).1995]), vesicular stomatitis peptide RGYVYQGL (VSV [van Bleek
and Nathenson, 1990]), and Sendai virus peptide FAPGNYPAL (SV9 Peptides in (A), (C), and (D) were pOV8 (open circles), VSV (filled
squares), and p2Ca-Y4 (filled triangles). Inhibition of lysis of SYRGL-[Schumacher et al., 1991]). Other peptides were LSPFYFDL (p2Ca-
Y5), SIIRFEKL (R-OV8), RGYRYQGL (R-VSV), and RGYVYQEL pulsed T2-Kb target cells by a polyclonal 2C CTL cell line is shown
in the presence of 1 mM of the peptides indicated (B).(EVSV).
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Figure 5. The Antagonist Peptide EVSV but Not the Null Peptide
pOV8 Reduced the TCR z Chain Tyrosine Phosphorylation InducedFigure 4. Soluble EVSV-Kb Complex Binds Specifically to the TCR
in Cloned 2C Cells that Had Been Exposed to the Strong Agoniston Live 2C Cells
Complex SYRGL-Kb
The ratio (B/Bo) is the amount of the 125I-Fab9 fragment of antibody
2C cells were exposed first to the SYRGL-Kb complex in lanes 1±31B2 bound to 2C cells in the absence (Bo) or presence (B) of various
and then exposed to PBS in lane 1, to the null OVA peptide (SIIN-concentrations of the EVSV-Kb complex. The equilibrium (affinity)
FEKL) in lane 2, or to the antagonist EVSV peptide (RGYVYQEL) inconstant for the reaction between 2C TCR and the EVSV-Kb complex
lane 3. In lanes 4±6 the cells were incubated only with OVA peptidewas derived from the best fit of the experimental points (filled circles)
(lane 4), EVSV peptide (lane 5), or PBS (lane 6). TCR z chain wasto the theoretical curve (solid curve) as previously described (Syku-
immunoprecipitated from all six samples by anti-TCR z antiseralev et al., 1994a).
(a-TCR z) and subjected to SDS-PAGE. The anti-phosphotyrosine
antibody (a-pTyr) was used for immunoblotting to detect phosphory-
of about 80% of TCR molecules on 2C cells. Can antago- lated tyrosines of TCR z chains (top panel). The same six samples
nist pMHC complexes on T2-Kb target cells occupy such were run in additional lanes of the same gel and immunoblotted
with anti-TCR z antisera to demonstrate that approximately equala large fraction of the TCR on 2C cells under our assay
amounts of TCR z chain were analyzed in the six samples (bottomconditions? The 2C TCR affinity for the EVSV-Kb antago-
panel).nist complex was measured to be about 9 3 104 L/M
(Figure 4; Table 1) or 1.5 3 10219 L/complex. To approach
80% occupancy of the TCR molecules in a reaction resulted in almost complete elimination of the agonist-
induced z chain tyrosine phosphorylation without affect-mixture [1.5 3 109; i.e., (105 TCR per cell) x (1.5 3 104 T
cells per well)] with this reaction's affinity would require ing the total amount of immunoprecipitated z chain
(compare lanes 1, 2, and 3). The effect shown differsthe density of the antagonist pMHC complexes to be
about one trillion (1 3 1012) per cell. However, the total from that described by Reis e Sousa et al. (1996), who
reported that there was less tyrosine phosphorylationnumber of Kb molecules is only about a half million (5 3
105) per target cell. Even if each pMHC complex engaged of CD3 z chains in CTL exposed to antagonist peptide
than in those exposed to agonist peptide, but more thanas many as 200 TCR molecules (Valitutti et al., 1995),
competition with agonist complexes for the TCR is a in those exposed to null (or no) peptide.
most unlikely explanation for the inhibitory effect of the
antagonist complexes. Discussion
Antagonist peptides on antigen-presenting cells in-
duce altered patterns of tyrosine phosphorylation of Two principal findings emerged from this study of pep-
tide antagonism. First, the affinity of the 2C TCR for anCD3 z chains in T cells (Sloan-Lancaster et al., 1994,
Madrenas et al., 1995). We therefore examined tyrosine antagonist pMHC (EVSV-Kb) was found to be higher than
for a weak agonist (p2Ca-Kb), although much lower thanphosphorylation of CD3 z chains in 2C cells that had
been exposed first to an agonist and then to an antago- for a strong agonist (SYRGL-Kb). Second, exposure of
activated 2C cells to the EVSV antagonist resulted in anist. To separate the effects of agonist and antagonist
complexes, we first confronted 2C cells for a few min- pronounced decrease in agonist-induced tyrosine phos-
phorylation of CD3 z chains. These findings are evalu-utes with SYRGL-Kb complexes adsorbed on plastic (96-
well plates). The cells were then removed from the immo- ated below with respect to various models proposed to
account for the inhibitory effects of antagonist peptides.bilized agonist complexes and incubated with either an
antagonist (EVSV) or null (pOV8) peptide. As shown pre- The models are largely focused on affinity and kinetics
of TCR-pMHC reactions. Since affinity values measuredviously, the binding of extracellular peptides to MHC
molecules on T cells can result in effective formation and for a given TCR under different conditions can, however,
differ substantially (see Table 2, below) we evaluatepresentation of the corresponding pMHC complexes by
the T cells to each other (Walden and Eisen, 1990; Su et these differences before considering our results in rela-
tion to the models.al., 1993). Figure 5 shows that exposure to the SYRGL-Kb
complex resulted in tyrosine phosphorylation of CD3 z In the present study and in a previous one (Sykulev
et al., 1994a), the 2C TCR affinity for the agonistschains (compare lanes 1 and 6) and subsequent expo-
sure to the EVSV antagonist, but not to the null ligand, SYRGL-Kb and p2Ca-Kb and the antagonist EVSV-Kb
Immunity
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were measured with the TCR in its natural environment difficult to deal with, as general procedures for determin-
ing the stability (i.e., dissociation rates) of TCR-pMHCon live 2C cells and with soluble pMHC complexes
formed from synthetic peptides and recombinant Kb and complexes on intact T cells have not yet been devel-
oped. Nevertheless, it is unlikely that the higher affinityLd molecules produced in Drosophila cells (Figures 1D
and 4; Sykulev et al., 1994a). As shown in Table 2, TCR reaction with the antagonist EVSV-Kb has a faster koff rate
constant than the approximately 30-fold lower affinityaffinity values measured under these conditions are con-
siderably higher than those determined in cell-free sys- reaction with the agonist p2Ca-Kb.
In an interesting kinetic discrimination model (Rabin-tems using soluble pMHC complexes formed in the
same way. One possible reason for the differences owitz et al., 1996), the binding of pMHC to TCR is as-
sumed to result in stepwise modifications (e.g., differentshown in Table 2 is that TCR-pMHC complexes can
be stabilized by CD8 molecules (Luescher et al., 1995; levels of phosphorylation of the receptor-CD3 complex):
incompletely modified receptors are assumed to elicitGarcia et al., 1996a), which are usually abundant on
intact CD81 cells and generally not present in cell-free negative signals and more extensively modified recep-
tors are assumed to elicit positive signals (cell activa-systems. Another possible reason is suggested by the
convoluted nature of the cell surface membrane and the tion), with the balance between the two determining the
extent to which a pMHC ligand acts as an antagonistabundance of TCR molecules on the T cell surface: a
pMHC complex that dissociates from a TCR molecule or a weak or strong agonist. In this model the steady
state level of the extensively modified receptor is deter-on the cell might thus have more opportunities than in
a cell-free system to rebind to the same or neighboring mined not by the rate at which the ligand dissociates
from the receptor per se (koff), but by the relative valuesTCR molecules (Valitutti et al., 1995).
Are the 2C TCR affinity values determined with intact of koff and the rate of transition (k2) from an incomplete
state of the receptor to a complete state. The model iscells (ªcellular affinityº) or in cell-free systems (ªcell-
free affinityº) more useful for our present purposes? thus compatible with an antagonist ligand such as EVSV-
Kb having a higher affinity and slower koff than an agonistMeasured on live T cells, the 2C TCR cellular affinity for
SYRGL-Kb is about 3000 times higher than for p2Ca-Kb such as p2Ca-KbÐif, for example, the transition rate k2
were much slower when the receptor is liganded with(Table 2; 1 3 107 M21 versus 3 3 103 M21). This difference
parallels the great difference in efficacy of the corre- an antagonist pMHC than with an agonist pMHC.
That the postulated rate of transition of ligated recep-sponding peptides in cytolytic assays with Kb target cells
(see Figures 1A and 1B). Similarly, the much greater tor from one state to another could vary with different
pMHC ligands raises the additional possibility that theeffectiveness of the QL9 than the p2Ca peptide in cyto-
lytic assays with Ld1 target cells is in accord with the TCR might assume a different conformation when bound
to an agonist or antagonist complex. This possibility is in2C TCR's having a 10 times higher cellular affinity for
QL9-Ld than p2Ca-Ld, but it is not in accord with this accord with recent evidence that soluble TCR molecules
dimerize on binding to agonist pMHC but not on bindingreceptor's having the same cell-free affinity for these
peptide-Ld complexes (Table 2; Sykulev et al., 1994a, to an antagonist pMHC (P. J. Travers and N. R. Gas-
coigne, personal communication). That a TCR can as-1994b). Moreover, the 2C TCR's cell-free affinity for
SYRGL-Kb and dEV8-Kb differed only around 2.5-fold sume different conformations resulting in various T cell
responses has been suggested previously (e.g., from(Garcia et al., 1996a; see Table 2); this small difference,
which is essentially within experimental error, is also not different responses of T cells to different anti-TCR anti-
bodies) (Rojo and Janeway, 1988; Yoon et al., 1994). Thein accord with the great difference in efficacy between
the corresponding peptides in cytolytic assays (Figure recent crystallographic studies of the 2C TCR (Garcia et
al., 1996b) provide a solid basis from which to search for1B). Differences in the binding of extracellular peptides
to Kb and Ld on target cells can certainly contribute to significant conformational differences between agonist-
and antagonist-liganded TCR.the disparate efficacies of these peptides in cytolytic
assays, but they cannot account for all of it; e.g., the The limited evidence now available indicates that the
changes in tyrosine phosphorylation of CD3 z chainsmillion-fold difference in peptide concentration required
for half-maximal lysis shown in Figure 1B. Thus, cellular elicited by an antagonist pMHC complex are quantita-
tively reduced but qualitatively the same as those elic-affinity values for agonist pMHC complexes generally
correlate more closely than cell-free affinity values with ited by agonist complexes (Reis e Sousa et al., 1996),
although actual sites of phosphorylation were not mapped.the behavior of peptides in cytolytic assays (see also
Sykulev et al., 1994a, 1994b). Therefore, in asking if The evidence presented here based on a somewhat
different experimental protocol (Figure 5) suggests, inaffinity values fit any of the models proposed to explain
agonist-antagonist differences, we think it reasonable contrast, that the antagonist complex stimulates re-
moval of phosphoryl groups from tyrosine residues into focus on cellular affinity values rather than on cell-
free values for both antagonists and agonists. CD3 z chains as though from the activation of a tyrosine
phosphatase (e.g., Neel, 1997). Since cellular responsesAccording to some views, TCR have lower affinity and
form less stable complexes with antagonist pMHC than to different altered peptide ligands can vary consider-
ably (anergy, weak agonism, antagonism at one concen-with agonist pMHC complexes (Lyons et al., 1996). The
suggestion with respect to affinity is clearly not univer- tration and agonism at another, or antagonism only),
it is possible that TCR interactions with these diversesally the case, as shown by the finding that the 2C
TCR has about 30 times higher affinity for an antagonist ligands can also elicit different patterns of protein tyro-
sine phosphorylation.(EVSV-Kb) than a weak agonist (p2Ca-Kb) complex (Fig-
ure 4; Sykulev et al., 1994a). The kinetic issue is more That peptide antagonism was more readily detected
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the amount of 51Cr released into extracellular medium. Percent spe-in 2C reactions with syngeneic pMHC than allogeneic
cific lysis was calculated from the following: (51Cr release into super-pMHC raises the possibility that allogeneic and synge-
natant 2 spontaneous release)/(total release in detergent 2 sponta-neic reactions might generally differ in susceptibility to
neous release) 3 100. Wells containing peptide were in duplicate.
antagonism. One reason for speculating about such a Similarly treated control wells (in quadruplicate) provided values for
difference is that in comparison with syngeneic pMHC, spontaneous release (CTL omitted) and total release (1% NP-40
included in medium).in allogeneic pMHC the MHC moiety may generally con-
To evaluate the ability of various peptides to inhibit specific lysistribute more, and the peptide less, to the binding energy
of Kb1 target cells by 2C CTL, the target cells were pulsed with theof TCR-pMHC interactions (Eisen et al., 1997). Thus, as
agonist peptide SYRGL by incubating them with this peptide whilein Table 1, variations in peptide length and sequence
the cells were being labeled with 51Cr (1 hr at 378C). The peptide
can have relatively little effect on equilibrium constants concentration was 4 3 10214 M for T2-Kb and 5 3 10212 M for the
when the involved MHC is allogeneic (Ld). Indeed, in other Kb1 target cells. Pulsed target cells were washed three times
to remove unbound peptide and unincorporated 51Cr and were mixedsome TCR reactions with allogeneic pMHC, the pep-
with various concentrations of the test peptides and CTL in round-tide's sequence appears not to matter at all, so long as
bottom 96-well plates as described above. Percent inhibition ofit stabilizes the MHC moiety (Smith et al., 1997; Zhou
specific lysis was calculated as 100 3 (A 2 B)/A, where A and Bet al., unpublished data). Even if they prove to be gener-
are percentages of specific lysis in the absence and presence of
ally less susceptible than syngeneic reactions to peptide the tested peptide.
antagonism, it appears that some alloreactions can also
be specifically inhibited by potent antagonist pMHC Peptide Binding to Kb and Ld
Equilibrium binding constant of SIYRYYGL (SYRGL) to Kb was esti-complexes (unpublished data).
mated in a peptide competition assay using as a reference peptide
RGYVYQGL (VSV), whose equilibrium (binding) constant for Kb pro-Experimental Procedures
tein (1 3 108 M21) was previously determined (Matsumura et al.,
1992). 51Cr-labeled T2-Kb target cells were incubated with SIINFEKLCells
(pOV8) peptide (at about 10211 M) and various dilutions of eitherCTL clones and cell lines that express the rearranged a and b chain
SYRGL or VSV; all peptides were added at the same time (unlikegenes of the 2C TCR were derived from 2C transgenic mice (Sha
the conditions used to pulse target cells in the antagonist assay;et al., 1988). Isolated splenocytes were initially stimulated with irradi-
see above). 4G3 CTLs (Walden and Eisen, 1990), which recognizeated P815 (H-2d) cells in K medium (RPMI supplemented with 10%
pOV8 in association with Kb, were then added at a CTL:target cellheat-inactivated fetal calf serum, 10 mM HEPES, 2 mM L-glutamine,
ratio of 3 to 1. Percent specific lysis, determined as described above100 U/ml penicillin, 100 mg/ml streptomycine, and 50 mM b-mercap-
after 4 hr incubation at 378C under 5% CO2, was plotted as a functiontoethanol) and restimulated 6 days later and thereafter at 1 week
of concentration of competing peptide. Equilibrium binding constantintervals with irradiated P815 cells (20 3 103 rad) in K medium con-
of Kb for RGYVYQEL (EVSV) was estimated in a peptide stabilizationtaining supernatants from concanavalin A (Con A)-activated rat
assay with the RMA-S cell line using reference peptides (VSV orsplenocytes. Established CTL lines was tested in cytotoxicity assays
pOV8); the affinities of Kb for the latter peptides were measuredusing 51Cr-labeled P815 cells and/or T2-Ld or T2-Kb cells sensitized
previously (Matsumura et al., 1992).with appropriate peptides as target cells (see below). Clones L3.100,
Equilibrium binding constants of a-ketoglutarate dehydrogenaseK2.30, and G3.1 were isolated from a 2C TCR1 CTL line by limiting
peptides to soluble Ld were measured by competition binding ofdilution in 96-well plates, initially with an average of 100, 30, and 1
these peptides and radiolabeled peptide from mouse cytomegalovi-cell per well, respectively. These clones were maintained and tested
rus (MCMV [Reddehase et al., 1989]) to the soluble Ld. Equilibriumas described above.
constant for the reaction between 125I-MCMV and soluble Ld wasThe human mutant cell line T2 (Alexander et al., 1989), transfected
determined in separate experiment. A detailed protocol for the assaywith Ld (T2-Ld) or Kb (T2-Kb) genes, was a generous gift from Dr. P.
was previously described (Matsumura et al., 1992).Cresswell (New Haven, CT); it was maintained as described else-
where (e.g., Sykulev et al., 1994a). EL4 thymoma cells (H-2b), RMA-S
Equilibrium Binding of Soluble Peptide-MHC Complexescells (H-2b TAP deficient), and P815 (H-2d) mastocytoma cells were
to 2C TCR on Intact Cellsall cultured in K medium.
The equilibrium binding constant for the TCR-pMHC reaction was
determined from the competition of soluble pMHC complexes withPeptides
125I-labeled Fab9 fragments of the clonotypic anti-TCR antibody 1B2The Biopolymers Laboratory of Massachusetts Institute of Technol-
for binding to the TCR on intact 2C cells, as previously describedogy synthesized the peptides used in this study (tBoc method) and
(Sykulev and Eisen, 1997). Soluble pMHC complexes were producedpurified many of them by HPLC. Peptide concentrations were based
by loading empty recombinant Kb and Ld proteins (Jackson et al.,on amino acid analyses or BCA assays or weight/volume.
1992) with an appropriate peptide at a concentration (1025 to 1026 M)
that was 100- to 1000-fold higher than the equilibrium dissociationSoluble MHC Class I Molecules
constant for the peptide-MHC reaction (i.e., sufficient to saturateSoluble Kb and Ld class I MHC molecules were expressed in Dro-
the MHC-binding sites for peptide).sophila melanogaster cells (Jackson et al., 1992) and isolated from
culture supernatants as described (Sykulev et al., 1994a). Soluble
peptide-Kb complexes used to study protein tyrosine phosphoryla- Tyrosine Phosphorylation of TCR z Chains
The wells of 24-well plates were coated by incubating 1±20 mg oftion in 2C TCR1 cells were produced in E. coli according to Nathen-
son and colleagues (Zhang et al., 1992). SYRGL-Kb complex per well at 48C overnight. Wells were then
washed with PBS, blocked with 1% BSA (in PBS) at 258C for 30±45
min, and washed with RPMI 1640 medium. 2C cells (3±10 3 106) inCytolytic Assay
In all experiments, 51Cr-labeled H-2Kb1 target cells (T2-Kb, EL4, or 500 ml of RPMI 1640 were added to each well, spun at 800 rpm for
2 min, and incubated at 378C under 5% CO2/95% air. After 20 min,RMA-S) and various 2C CTL clones or 2C cell lines (expressing
transgenic 2C TCR) were used. Usually 5,000 target cells (in 100 ml the 2C cells were transferred to Eppendorf tubes containing 50 ml
of 1025 M test peptide (EVSV or OVA) in PBS or 50 ml of PBS withoutK medium) and 25,000 CTL (in 50 ml K medium) were combined with
50 ml of PBS containing various peptides at different concentrations peptide and incubated for 20 min at 378C under 5% CO2/95% air.
For further controls, cells were not exposed to SYRGL-Kb but werein round-bottom 96-well plates. The plates were centrifuged (for 1±2
min) at 500 g and then incubated at 378C in a 5% CO2/95% air incubated under similar conditions with test peptide (EVSV or OVA)
or no peptide at all. Equal volumes (≈500 ml) of ice-cold PBS con-atmosphere. After 4 hr, the plates were centrifuged for 5 min and
100 ml of supernantant was harvested from each well to determine taining 1 mM sodium orthovanadate were then added to all six
Immunity
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samples and the tubes were transferred to ice. Cells were pelleted of stable T-cell recptor/MHC class I molecule complexes. Nature
384, 577±581.at 14,000 rpm for 20 s, and pellets were lysed in 50±100 ml of lysis
buffer (1% NP-40, 150 mM NaCl, 10 mM Tris-HCl [pH 8.0], 5 mM Garcia, K.C., Degano, M., Stanfield, R.L., Brunmark, A., Jackson,
EDTA, 1 mM sodium orthovanadate, 10 mg/ml leupeptin, 10 mg/ml M.R., Peterson, P.A., Teyton, L., and Wilson, I.A. (1996b). An ab T
aprotinin, and 1 mM PMSF). Lysates were precleared with normal cell receptor structure at 2.5 AÊ and its orientation in the TCR-MHC
rabbit serum and formalin fixed Staphylococcus aureus and then complex. Science 274, 209±219.
immunoprecipitated with TCR z-specific rabbit antiserum (a gener- Garcia, K.C., Tallquist, M.D., Pease, L.R., Brunmark, A., Scott, C.A.,
ous gift of Dr. P. Allen, St. Louis, MO). The immunoprecipitated Degano, M., Stura, E.A., Peterson, P.A., Wilson, I.A., and Teyton,
proteins were separated by 12.5% SDS-PAGE under reducing con- L. (1997). An ab T cell receptor interactions with syngeneic and
ditions and blotted onto nitrocellulose. The blots were probed with allogeneic ligandsÐaffinity measurements and crystallization. Proc.
either the anti-phosphotyrosine monoclonal antibody (clone 4G10 Natl. Acad. Sci. USA 94, 13838±13843.
[UBI, Lake Placid, NY]) or the TCR z-specific antisera; in both in-
Jackson, M.R., Song, E.S., Yang, Y., and Peterson, P. (1992). Emptystances they were followed by peroxidase-conjugated goat antibod-
and peptide-containing conformers of class I major histocompatibil-
ies to mouse or rabbit immunoglobulins (Pharmingen) and were
ity complex molecules expressed in Drosophila melanogaster cells.
developed by chemiluminescence.
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